<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01453283</url>
  </required_header>
  <id_info>
    <org_study_id>070054</org_study_id>
    <secondary_id>07-C-0054</secondary_id>
    <nct_id>NCT01453283</nct_id>
    <nct_alias>NCT00437047</nct_alias>
  </id_info>
  <brief_title>Tabectedin to Treat Children and Adolescents With Cancer</brief_title>
  <official_title>A Phase I Trial and Pharmacokinetic Study of Trabectedin (YONDELIS [R], ET-743) in Children and Adolescents With Relapsed or Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
        -  Trabectedin is an experimental drug that kills some cancer cells in the laboratory and&#xD;
           in mice by interfering with genetic material (DNA) in cancer cells.&#xD;
&#xD;
        -  In some adult patients with cancer who received trabectedin, tumors grew slower or&#xD;
           shrank.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
        -  To determine a dose of trabectedin that can be given safely to children and adolescents&#xD;
           as a 24-hour continuous infusion through a vein.&#xD;
&#xD;
        -  To determine the side effects of trabectedin in children and adolescents.&#xD;
&#xD;
        -  To study how the body handles trabectedin by measuring the amount of the drug in the&#xD;
           bloodstream over time after a dose is given.&#xD;
&#xD;
        -  To measure the effect of trabectedin on DNA in white blood cells.&#xD;
&#xD;
        -  To determine if an individual's tumor cells have a specific proteins involved in DNA&#xD;
           repair and if a pattern of genes can be identified in tumor samples that might help&#xD;
           explain why trabectedin reduces tumors in some individuals and not others.&#xD;
&#xD;
        -  To study genetic factors that may influence the way the body handles trabectedin.&#xD;
&#xD;
        -  To see if trabectedin is beneficial in certain types of cancer.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      -Children between 4 year and 17 years of age with tumors that recur or no longer respond to&#xD;
      standard treatment.&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  Patients receive trabectedin as a 24-hour continuous infusion repeated every 21 days.&#xD;
           The first three children entering the study receive a dose of 1.1 mg/m2. Subsequent&#xD;
           groups of up to six patients receive higher doses (1.5 mg/m2 and 1.7 mg/m2) as long as&#xD;
           the preceding dose is well tolerated. Patients enrolled at the lowest dose level may&#xD;
           have their dose increased to the next level if they tolerated the lower dose well.&#xD;
           Treatment may continue as long as the cancer does not worsen and the treatment is&#xD;
           tolerated.&#xD;
&#xD;
        -  Patients have blood drawn on days 1, 2, 3, 4, 5 and 7 of the first treatment cycle to&#xD;
           study how the body handles trabectedin.&#xD;
&#xD;
        -  A tumor sample obtained from a prior surgery or biopsy is examined for proteins involved&#xD;
           in DNA repair.&#xD;
&#xD;
        -  A blood sample is drawn to look for genetic factors that may influence how the body&#xD;
           handles trabectedin.&#xD;
&#xD;
        -  Patients have periodic physical examinations and blood tests. MRI or CT scans are done&#xD;
           before starting therapy and after every two treatment cycles to evaluate the tumor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
      Trabectedin (ET-743) is a natural product derived from the marine tunicate Ecteinascidia&#xD;
      turbinata. It binds to the minor groove of DNA and interacts with various transcription&#xD;
      factors resulting in cell cycle arrest. It also inhibits transcription coupled nucleotide&#xD;
      excision repair system inducing lethal DNA strand breaks.&#xD;
&#xD;
      In preclinical and clinical studies, trabectedin has been found to be active in many soft&#xD;
      tissue sarcomas including leiomyosarcoma, synovial cell sarcoma, neuroblastoma,&#xD;
      rhabdomyosarcoma, melanoma, breast, ovarian, non-small cell lung, renal and prostate&#xD;
      carcinoma.&#xD;
&#xD;
      In adult phase I and phase II studies, trabectedin has been well-tolerated up to dose levels&#xD;
      of 1.9mg/m(2)/dose with the most common toxicities being fatigue, neutropenia, and reversible&#xD;
      transaminase elevations. Objective responses were seen at doses equal to or greater than&#xD;
      1.5mg/m(2)/dose. Trabectedin 1.5mg/m(2) administered as a 24-hour continuous intravenous&#xD;
      infusion is the recommended dose and schedule in adults.&#xD;
&#xD;
      A pediatric phase I study of trabectedin administered as a 3-hour infusion has been completed&#xD;
      in the Children's Oncology Group. The maximum tolerated dose was 1.1 mg/m(2). Dose limiting&#xD;
      toxicity was reversible elevation of hepatic transaminases.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      Determine the maximum tolerated dose (MTD) of trabectedin administered as a 24-hour&#xD;
      continuous infusion in children and adolescents with relapsed or refractory solid tumors.&#xD;
&#xD;
      Define the toxicity profile of trabectedin administered as a 24-hr infusion in children and&#xD;
      adolescents.&#xD;
&#xD;
      Describe the pharmacokinetics of trabectedin administered as a 24-hr infusion in children and&#xD;
      adolescents.&#xD;
&#xD;
      Quantify double strand DNA breaks in peripheral blood mononuclear cells of patients receiving&#xD;
      trabectedin.&#xD;
&#xD;
      Evaluate archival formalin fixed paraffin embedded tumor tissue, when available from prior&#xD;
      biopsies or surgical procedures, for the expression of the nucleotide excision repair&#xD;
      proteins and genomic instability markers (histone gamma-H2AX, phospho-ATM, phospho-Chk2) by&#xD;
      immunohistochemistry&#xD;
&#xD;
      Molecular characterization of DNA repair genes and correlation to outcome using mRNA isolated&#xD;
      from microdissected archival formalin fixed, paraffin embedded tumor sections.&#xD;
&#xD;
      Study the pharmacogenetics of host DNA repair proteins and drug metabolizing enzymes to&#xD;
      explore the impact of host factors on trabectedin toxicity.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      Children greater than or equal to 4 years and less than 17 years of age with relapsed or&#xD;
      refractory solid tumors.&#xD;
&#xD;
      Design:&#xD;
&#xD;
      Patients will receive trabectedin as a 24-hour continuous infusion repeated every 21 days.&#xD;
      The starting dose level is 1.1mg/m(2)/dose with escalations to 1.5mg/m(2)/dose and&#xD;
      1.7mg/m(2)/dose.&#xD;
&#xD;
      All patients will receive dexamethasone pretreatment and growth factor support with&#xD;
      filgrastim or pegfilgrastim.&#xD;
&#xD;
      The definition of dose-limiting hepatic toxicity will be identical to the definition used in&#xD;
      phase I trials in adults on the same dosing schedule.&#xD;
&#xD;
      Pharmacokinetic analysis will be performed on days 1, 2, 3, 4, 5 and 7 of the first treatment&#xD;
      cycle.&#xD;
&#xD;
      Three to six patients will be enrolled at the first dose level and up to 6 patients will be&#xD;
      enrolled on subsequent dose levels. Dose escalation will be based on tolerability of&#xD;
      trabectedin at the prior dose level. For patients enrolled at dose level 1 (1.1mg/m(2)),&#xD;
      intrapatient dose escalation to dose level 2 (1.5mg/m(2)) will be allowed with subsequent&#xD;
      cycles if no dose limiting toxicities occurred at the lower dose level. Total accrual will be&#xD;
      up to 24 patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 20, 2006</start_date>
  <completion_date type="Actual">October 11, 2011</completion_date>
  <primary_completion_date type="Actual">October 11, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">12</enrollment>
  <condition>Solid Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trabectedin (ecteinascidin-743, ET-743, YONDELIS [R])</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        AGE: greater than or equal to 4 years and less than 17 years of age.&#xD;
&#xD;
        DIAGNOSIS: Histologically confirmed solid tumors, which may include but are not limited to&#xD;
        rhabdomyosarcoma and other soft tissue sarcomas, Ewing's sarcoma family of tumors,&#xD;
        osteosarcoma, neuroblastoma, Wilms' tumor, hepatic tumors, germ cell tumors, and brain&#xD;
        tumors with the exception that histologic confirmation is not required for patients with&#xD;
        optic or brainstem gliomas.&#xD;
&#xD;
        MEASURABLE/EVALUABLE DISEASE: Patients must have measurable or evaluable disease.&#xD;
&#xD;
        PRIOR THERAPY: The patient's cancer must have relapsed after or failed to respond to&#xD;
        frontline curative therapy and there must not be other potentially curative treatment&#xD;
        options available.&#xD;
&#xD;
          -  Patients must have fully recovered to less than or equal to grade 1 from the acute&#xD;
             toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to&#xD;
             entering this study.&#xD;
&#xD;
          -  Myelosuppressive chemotherapy: The last dose of all myelosuppressive anticancer drugs&#xD;
             must be at least 3 weeks prior to study entry.&#xD;
&#xD;
          -  Growth factors: The last dose of growth factors such as filgrastim and epoetin must be&#xD;
             at least one week prior to study entry, the last dose of long-acting colony&#xD;
             stimulating factors, such as pegfilgrastim, must be 2 weeks prior to study entry.&#xD;
&#xD;
          -  Investigational anti-cancer agents: The last dose of all investigational agents must&#xD;
             be at least 30 days prior to study entry.&#xD;
&#xD;
          -  Biologic anti-cancer agents: The last dose of non-myelosuppressive biologic agents for&#xD;
             the treatment of the patient's cancer (example, retinoids) must be at least 7 days&#xD;
             prior to study entry.&#xD;
&#xD;
          -  Radiation therapy: The last dose of radiation to more than 25% of marrow containing&#xD;
             bones (pelvis, spine, skull) must be at least 4 weeks prior to study entry, TBI and&#xD;
             craniospinal radiation must be completed at least 4 months prior to study entry. The&#xD;
             last dose of all other local palliative radiation must be at least 2 weeks prior to&#xD;
             study entry.&#xD;
&#xD;
          -  Stem Cell Transplantation. Patients must be at least 2 months post-autologous&#xD;
             transplant and recovered from treatment-related toxicities. Patients who have received&#xD;
             an allogeneic transplant are excluded.&#xD;
&#xD;
        CONCOMITANT MEDICATIONS:&#xD;
&#xD;
        -Patients with brain tumors must be on a stable or tapering dose of corticosteroids for 7&#xD;
        days prior to the date of the baseline scan performed for the purpose of assessing response&#xD;
        to therapy on this study.&#xD;
&#xD;
        PERFORMANCE STATUS: Patients must have a Lansky (less than or equal to 10 years old) or&#xD;
        Karnofsky (greater than 10 years old) score of greater than or equal to 60%.&#xD;
&#xD;
        HEMATOLOGIC FUNCTION: Peripheral absolute neutrophil count greater than or equal to&#xD;
        1,500/microliter and a platelet count greater than or equal to 75,000/microliter&#xD;
        independent of transfusion, and a hemoglobin of greater than or equal to 8 gm/dl&#xD;
        (transfusion permitted to achieve this level).&#xD;
&#xD;
        HEPATIC FUNCTION:&#xD;
&#xD;
          -  ALT (SGPT) and AST (SGOT) must be less than or equal to 2.5 x the upper limit of&#xD;
             normal (ULN).&#xD;
&#xD;
          -  Bilirubin must be less than or equal to ULN. If the patient has Gilbert's syndrome,&#xD;
             normal bilirubin is not required but should be discussed with the PI or study chair.&#xD;
&#xD;
          -  Alkaline phosphatase must be less than or equal to ULN for age and sex or if alkaline&#xD;
             phosphatase greater than ULN then 5' nucleotidase must be less than or equal to ULN or&#xD;
             the gamma-glutamyl transpeptidase (GGT) must be less than or equal to 2.5 times the&#xD;
             ULN to be eligible.&#xD;
&#xD;
        Normal Values for Alkaline Phosphatase at the NIH Clinical Center (U/L):&#xD;
&#xD;
        Age between 4 to 6 years with a normal value (U/L) in Males 93 to 309 and a normal value&#xD;
        (U/L) in Females 96 to 297.&#xD;
&#xD;
        Age between 7 to 9 years with a normal value (U/L) in Males 86 to 315 and a normal value&#xD;
        (U/L) in Females 69 to 325.&#xD;
&#xD;
        Age between 10 to 12 years with a normal value (U/L) in Males 42 to 362 and a normal value&#xD;
        (U/L) in Females 51 to 332.&#xD;
&#xD;
        Age between 13 to 15 years with a normal value (U/L) in Males 74 to 390 and a normal value&#xD;
        (U/L) in Females 50 to 162.&#xD;
&#xD;
        Age between 16 to 18 years with a normal value (U/L) in Males 52 to 171 and a normal value&#xD;
        (U/L) in Females 47 to 119.&#xD;
&#xD;
        OTHER: creatine kinase less than or equal to 2.5 times the ULN.&#xD;
&#xD;
        RENAL FUNCTION: Age-adjusted serum creatinine OR a creatinine clearance greater than or&#xD;
        equal to 60 mL/min/1.73 m(2).&#xD;
&#xD;
        Age less than or equal to 5 with a serum creatinine less than or equal to 0.8 (mg/dl).&#xD;
&#xD;
        Age greater than 5 years and less than or equal to 10 with a serum creatinine of less than&#xD;
        or equal to 1.0 (mg/dl).&#xD;
&#xD;
        Age greater than 10 and less than or equal to 15 with a serum creatinine less than or equal&#xD;
        to 1.2 (mg/dl).&#xD;
&#xD;
        Age greater than 15 with a serum creatinine less than or equal to 1.5 (mg/dl).&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        Patients with severe uncontrolled infections or other unrelated systemic illnesses, which&#xD;
        in the judgment of the Principal or Associate Investigator would compromise the patient's&#xD;
        ability to tolerate trabectedin or are likely to interfere with the study procedures or&#xD;
        results.&#xD;
&#xD;
        Patients with known history of xeroderma pigmentosum or other diseases with reduced DNA&#xD;
        repair.&#xD;
&#xD;
        Pregnant or breast-feeding females. Sexually active patients must be willing to use an&#xD;
        effective form of birth control.&#xD;
&#xD;
        Patients currently receiving other investigational agents.&#xD;
&#xD;
        Patients who have received allogeneic stem cell transplants.&#xD;
&#xD;
        Patients who have had prior therapy with trabectedin (ET-743, Yondelis).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Howard A Fine, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gillet LC, Sch√§rer OD. Molecular mechanisms of mammalian global genome nucleotide excision repair. Chem Rev. 2006 Feb;106(2):253-76. Review.</citation>
    <PMID>16464005</PMID>
  </reference>
  <reference>
    <citation>Suk R, Gurubhagavatula S, Park S, Zhou W, Su L, Lynch TJ, Wain JC, Neuberg D, Liu G, Christiani DC. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. Clin Cancer Res. 2005 Feb 15;11(4):1534-8.</citation>
    <PMID>15746057</PMID>
  </reference>
  <reference>
    <citation>Aune GJ, Furuta T, Pommier Y. Ecteinascidin 743: a novel anticancer drug with a unique mechanism of action. Anticancer Drugs. 2002 Jul;13(6):545-55. Review.</citation>
    <PMID>12172500</PMID>
  </reference>
  <verification_date>April 4, 2012</verification_date>
  <study_first_submitted>October 1, 2011</study_first_submitted>
  <study_first_submitted_qc>October 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2011</study_first_posted>
  <last_update_submitted>June 30, 2017</last_update_submitted>
  <last_update_submitted_qc>June 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <name_title>Brigitte C. Widemann, M.D./National Cancer Institute</name_title>
    <organization>National Institutes of Health</organization>
  </responsible_party>
  <keyword>DNA Repair</keyword>
  <keyword>Nucleotide Excision Repair</keyword>
  <keyword>Trabectedine</keyword>
  <keyword>Phase I</keyword>
  <keyword>Sarcoma</keyword>
  <keyword>Cytotoxic</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Solid Tumor</keyword>
  <keyword>Malignant Tumor</keyword>
  <keyword>Rhabdomyosarcoma</keyword>
  <keyword>Ewing Sarcoma</keyword>
  <keyword>Neuroblastoma</keyword>
  <keyword>Wilm's Tumor</keyword>
  <keyword>Hepatic Tumor</keyword>
  <keyword>Brain Tumor</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trabectedin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

